Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Use of Antiemetic Agents in Acute Gastroenteritis 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease
Your Article Summary
See Latest ArticlesRole of fixed-combination brinzolamide 1%/timolol 0.5% in the treatment of elevated intraocular pressure in open-angle glaucoma and ocular hypertension
Clinical Ophthalmology, 10/23/09
Beckers HJM et al. – Brinzolamide 1%/timolol 0.5% is a new fixed–combination for the treatment of open–angle glaucoma or ocular hypertension. Brinzolamide/timolol has a favorable safety profile, with an incidence of ocular burning and stinging <5%. Published data show that brinzolamide 1%/timolol 0.5% and dorzolamide 2%/timolol 0.5% have similar efficacies for lowering intraocular pressure.
Related Articles
Glaucoma and dry eye data from Germany
Ophthalmology Times Europe, 10/27/09
Relevance Score: 93%
Understanding the Importance of IOP Variables in Glaucoma
Survey of Ophthalmology, 10/23/09
Relevance Score: 92%
Characteristics of respondents with glaucoma and dry eye in a national panel survey
Clinical Ophthalmology, 11/13/09
Relevance Score: 91%
Gene-directed therapy in glaucoma may have future clinical applications
Ophthalmology Times Europe, 10/22/09
Relevance Score: 91%
Sequential Glaucoma Implants in Refractory Glaucoma
American Journal of Ophthalmology, 10/20/09
Relevance Score: 91%
Today in Ophthalmology...keeping you current
Receive free subspecialty "5-minute updates" via email
A 1-Year Retrospective Review of Ranibizumab for Naive Nonsubfoveal Choroidal Neovascularization Secondary To Age-Related Macular Degeneration
Retina, 11/25/09
Sponsor
Article Search
Sponsor
Sponsor